GH Secretagogue Combination Therapy

CJC-1295 (No DAC) / Ipamorelin Blend

Growth Hormone Optimization · Body Composition · Athletic Recovery · Longevity & Anti-Aging

Intended Audience: Licensed physicians and advanced practitioners integrating peptide-based GH secretagogue therapy, body recomposition, athletic recovery, metabolic enhancement, and longevity protocols.

GHRH Analog (CJC-1295 No DAC) + GHSR1a Agonist (Ipamorelin) → Dual-receptor activation producing synergistic GH pulse amplification

1. Clinical Overview

Blend Classification: GHRH Analog (CJC-1295 No DAC) + Selective Growth Hormone Releasing Peptide (Ipamorelin)

Mechanism Class: Dual-pathway GH secretagogue combination · Pituitary somatotroph activator · IGF-1 axis stimulator

Half-lives: CJC-1295 No DAC ≈ 30 minutes (GHRH pathway) · Ipamorelin ≈ 2 hours (ghrelin/GHSR1a pathway)

Primary Route: Subcutaneous injection · Often co-administered in same syringe

The CJC-1295 (No DAC) / Ipamorelin blend is the most widely utilized GH-secretagogue combination in modern peptide and functional medicine. By simultaneously activating two distinct and complementary pituitary receptor pathways, the blend produces a synergistic GH pulse that neither agent can achieve independently — while preserving the natural pulsatile rhythm critical for long-term receptor sensitivity and efficacy.

CJC-1295 (No DAC)	Ipamorelin
GHRH analog — tetrasubstituted GHRH (1-29)	Selective GHRP — pentapeptide ghrelin mimic
Binds pituitary GHRH receptors (Gs / cAMP pathway)	Binds ghrelin/GHSR1a receptors (Gq / calcium pathway)
Amplifies GH pulse amplitude and duration	Triggers pulsatile GH release from somatotrophs
Half-life ~30 min; rapid onset, short window	Half-life ~2 hr; sustained ghrelin receptor stimulation
Best paired with a GHRP for maximum effect	No cortisol, prolactin, or ACTH elevation

2. Mechanisms of Synergy — Why the Blend Outperforms Monotherapy

2.1 Dual-Receptor Activation

GH release from pituitary somatotrophs is regulated by two independent neuroendocrine pathways. CJC-1295 (No DAC) activates the GHRH receptor via Gs-protein/cAMP/PKA signaling, promoting GH synthesis and release. Ipamorelin activates GHSR1a via Gq-protein, mobilizing intracellular calcium to trigger exocytosis of GH granules. When both are activated simultaneously, the calcium mobilization from GHSR1a potentiates the cAMP-driven release — generating GH pulses substantially greater in amplitude than either agent alone.

KEY PRINCIPLE: CJC-1295 (No DAC) primes and extends the GH release window. Ipamorelin triggers the pulse. Together, they produce a GH surge that mimics youthful, physiological GH secretion at a fraction of the cost and risk of exogenous recombinant HGH therapy.

2.2 Complementary Pharmacokinetics

Pharmacokinetic Feature	Blend Advantage
CJC-1295 No DAC: ~30 min half-life	Rapid GHRH receptor occupancy; immediate pulse onset
Ipamorelin: ~2 hour half-life	Sustained ghrelin receptor stimulation; extended GH window
Both short-acting, pulsatile profiles	Preserves physiological GH rhythm — avoids tachyphylaxis
Compatible in same syringe	Single injection activates both pathways simultaneously

2.3 Extended GH Pulse Profile

CJC-1295 (No DAC) rapidly initiates GH pulse onset via GHRH receptor occupancy
Ipamorelin's longer half-life continues GHSR1a stimulation after CJC's effect wanes — extending the release window
Net result: longer-duration, higher-amplitude GH pulse vs. either monotherapy
Downstream IGF-1 production is proportionally amplified, magnifying all anabolic and metabolic benefits

2.4 Preserved Pulsatile GH Physiology

Unlike exogenous rhGH or DAC-containing peptides that flatten GH secretion into continuous elevation, the No DAC / Ipamorelin blend preserves the natural pulsatile GH rhythm. Pulsatile release maintains GH receptor sensitivity for long-term efficacy, supports IGF-1 oscillation associated with better body composition outcomes, and avoids the metabolic risks associated with sustained GH elevation.

3. Blend vs. Monotherapy — Clinical Comparison

3.1 Blend vs. CJC-1295 (No DAC) Alone

CJC-1295 (No DAC) Alone	CJC-1295 + Ipamorelin Blend
Stimulates GHRH pathway only	Activates GHRH + ghrelin pathways simultaneously
Moderate GH pulse amplitude	Substantially higher GH pulse amplitude (synergistic)
Response dependent on endogenous ghrelin	Ghrelin pathway actively stimulated; consistent response
Good for sleep and anti-aging	Superior sleep, tissue repair, and body composition outcomes

3.2 Blend vs. Ipamorelin Alone

Ipamorelin Alone	CJC-1295 + Ipamorelin Blend
Stimulates ghrelin/GHSR1a pathway only	GHRH pathway co-activated; amplified GH output
Excellent tolerability and clean profile	Clean profile fully preserved; no new safety concerns
Moderate GH pulse; limited duration	Extended pulse duration from CJC-1295 GHRH priming
Solid for sleep, recovery, anti-aging	Superior for recomposition, performance, and longevity

3.3 When to Use Monotherapy vs. Blend

Clinical Scenario	Recommended Approach
Mild sleep optimization only	Ipamorelin alone (200 mcg nightly) may suffice
First-time / introductory protocol	Blend at 100/100 mcg — establishes tolerability
Body recomposition (fat loss + lean mass)	Blend strongly preferred — synergy is essential
Athletic recovery and performance	Blend at 200/200 or 300/300 mcg BID
Anti-aging and longevity maintenance	Blend preferred; 5-on/2-off cycling recommended
Budget constraints / maintenance phase	Ipamorelin alone as a cost-effective maintenance option

4. Administration & Blend Dosing Protocols

The blend is administered subcutaneously. Both peptides are compatible in solution and may be drawn into the same syringe or injected at the same anatomical site in rapid sequence. Rotate injection sites.

4.1 Standard Dosing Tiers

Tier	CJC-1295 (No DAC)	Ipamorelin	Frequency	Best For
Introductory	100 mcg	100 mcg	Once nightly pre-bed	New patients; tolerability assessment
Standard	100–200 mcg	200 mcg	Once nightly pre-bed	Sleep, recovery, anti-aging, wellness
Performance	200 mcg	200–300 mcg	BID (AM fasted + pre-bed)	Fat loss, lean mass, athletic recovery
Advanced	200–300 mcg	300 mcg	BID–TID	Body recomposition, elite athletes

4.2 Reconstitution Reference

Standard vial (2 mg): Add 1 mL bacteriostatic water → 2000 mcg/mL
200/200 dose: Draw 0.10 mL CJC + 0.10 mL Ipamorelin = 0.20 mL total
100/100 dose: Draw 0.05 mL CJC + 0.05 mL Ipamorelin = 0.10 mL total
Storage: Refrigerate reconstituted peptides at 2–8°C. Use within 30 days. Do not shake — gently swirl.
Note: Pre-mixed blend vials simplify preparation and reduce patient injection burden.

5. Timing Protocols — Pre-Bed vs. AM Dosing

Injection timing is a critical determinant of clinical outcomes. The pituitary releases GH in synchrony with circadian rhythms and nutritional status. Strategic timing amplifies outcomes significantly.

5.1 Pre-Bed Dosing (Primary — Most Important)

Timing: 30–90 minutes before sleep | Empty stomach (no food 2+ hours prior)
Dose: 100/100 to 200/200 mcg SC

Why this is the most important dose:
• Natural GH secretion peaks during the first 2 hours of slow-wave (deep) sleep
• Pre-bed injection synchronizes the pharmacologic GH pulse with this natural nocturnal peak — dramatically amplifying the combined pulse
• GH released during sleep directly drives overnight tissue repair, muscle recovery, and cellular regeneration
• Ipamorelin independently improves sleep architecture via ghrelin-related pathways

Clinical outcomes: Improved sleep depth (SWS), enhanced morning recovery, better body composition results, higher overnight IGF-1 secretion

5.2 AM Fasted Dosing (Second Dose — Performance & Fat Loss)

Timing: Upon waking | Fasted (minimum 1 hour before food)
Dose: 100/100 to 200/200 mcg SC

Why add an AM dose:
• GH is strongly lipolytic — a fasted AM pulse dramatically enhances fat mobilization
• Morning cortisol is at its daily peak; GH counters cortisol's catabolic effects on lean mass
• Combined with fasted exercise, fat loss outcomes are significantly amplified
• Doubles total daily IGF-1 production, accelerating lean mass gains

Best for: Body recomposition, fat loss, athletic performance, post-surgical recovery
Avoid: Eating within 30–60 minutes post-injection to preserve GH pulse integrity

5.3 Timing Protocol Summary by Goal

Clinical Goal	Dosing Schedule	Key Timing Note
Sleep optimization	200/200 once nightly pre-bed	Inject 30–90 min before sleep; fasted
Anti-aging / longevity	100–200/200 nightly	Pre-bed; 5 days on / 2 days off
Fat loss	200/200 AM + 200/200 PM	AM: fasted on waking; PM: pre-bed
Body recomposition	200/200 AM + 200/200 PM	AM dose pre-workout if possible
Injury recovery	200/200 once or BID	Pre-bed primary; BID for accelerated recovery
Hormone optimization adjunct	100–200/200 nightly	Pre-bed for circadian synergy with TRT/HRT

5.4 Critical Timing Rules

Do not inject within 2 hours of a meal. Elevated insulin suppresses GH release and blunts peptide effect — the most common patient compliance error.
No more than 3 doses per day. The pituitary requires refractory periods between pulses to maintain receptor sensitivity.
Do not inject pre-workout after carbohydrate intake. Post-carb insulin elevation significantly reduces GH pulse amplitude.
Synchronization with circadian rhythms is not optional — it is the mechanism. Random timing yields substantially inferior outcomes.

6. Clinical Applications

6.1 Body Composition & Metabolic Enhancement

Visceral and subcutaneous fat reduction via GH-mediated lipolysis
Lean muscle preservation during caloric deficit; enhanced protein synthesis
Increased resting metabolic rate via IGF-1 signaling
Improved insulin sensitivity with long-term GH-axis optimization
Synergistic with SLU-PP-332, 5-Amino-1MQ, and MOTS-c for comprehensive metabolic protocols

6.2 Recovery & Tissue Repair

GH/IGF-1 axis drives protein synthesis and muscle fiber repair
Accelerates connective tissue remodeling and collagen synthesis
Post-surgical recovery support — wound healing and immune function
Powerfully synergistic with BPC-157 and TB-500 for musculoskeletal protocols

6.3 Sleep Architecture & Circadian Optimization

Increases slow-wave (deep) sleep duration and quality
Supports GH circadian rhythm restoration in aging patients
Reduces sleep fragmentation in stress-related insomnia
Synergistic with DSIP for comprehensive sleep protocols

6.4 Longevity & Anti-Aging

GH/IGF-1 decline begins at ~age 30; blend supports physiological restoration
Skin collagen density improvement via GH-driven fibroblast activity
Bone mineral density support through IGF-1 osteoblast stimulation
Mitochondrial function in combination with NAD+, SS-31, MOTS-c
Cognitive vitality via GH-IGF-1 neuroprotective signaling

6.5 Hormone Optimization (Adjunct)

Not a replacement for TRT, HRT, or thyroid therapy. Provides significant synergistic support in comprehensive hormone optimization: amplifies anabolic response to testosterone therapy, supports thyroid hormone conversion, and addresses the GH-deficiency component of andropause and menopause symptom burden.

7. Clinical Decision Trees

Tree 1 — Is the CJC-1295 / Ipamorelin Blend Indicated?

Fatigue, low energy, or poor morning recovery? → Blend indicated

Poor sleep quality or insomnia? → Blend indicated

Stubborn body fat or inability to build lean mass? → Blend strongly preferred

Slow recovery from exercise, injury, or surgery? → Blend indicated

Age-related GH decline (onset ~age 30)? → Blend indicated

Inadequate response to TRT/HRT alone? → Blend as adjunct

Budget-sensitive / maintenance phase? → Consider Ipamorelin monotherapy

Tree 2 — Dose & Timing Selection

Sleep / recovery / anti-aging goal? → 100–200/200 mcg SC pre-bed nightly

Fat loss / body recomposition goal? → 200/200 mcg BID (AM fasted + pre-bed)

Athletic performance / injury recovery? → 200–300/300 mcg BID

Longevity maintenance protocol? → 100–200/200 mcg pre-bed, 5 on / 2 off

New patient / first cycle? → Start 100/100 × 4 weeks, then titrate

Tree 3 — Cycle Duration

New patient / introductory: → 4–6 weeks at 100/100 nightly

Standard therapeutic: → 8–12 weeks; 4–8 week off period

Advanced: → 16–24 weeks at 200/200 BID; periodic IGF-1 monitoring

Long-term maintenance: → 5 days on / 2 days off indefinitely; annual lab review

8. Integrated Treatment Archetypes

Archetype A — Body Recomposition Protocol

Peptide / Product	Dose	Timing
CJC-1295 (No DAC) / Ipamorelin Blend	200/200 mcg SC	AM (fasted) + Pre-bed
SLU-PP-332	Per protocol	AM
5-Amino-1MQ	Per protocol	AM with breakfast
MOTS-c	Per protocol	Weekly

Outcome: Increased lean mass, accelerated visceral fat reduction, improved metabolic flexibility.

Archetype B — Recovery & Injury Repair Protocol

Peptide / Product	Dose	Timing
CJC-1295 (No DAC) / Ipamorelin Blend	200/200 mcg SC	Pre-bed (add AM for severe cases)
BPC-157	250–500 mcg SC	Daily near injury site
TB-500	2–5 mg SC	Weekly

Outcome: Accelerated musculoskeletal healing, reduced recovery time, enhanced post-surgical repair.

Archetype C — Longevity & Anti-Aging Protocol

Peptide / Product	Dose	Timing
CJC-1295 (No DAC) / Ipamorelin Blend	100–200/200 mcg SC	Pre-bed nightly
Epitalon	5–10 mg SC	Quarterly courses
NAD+	Per protocol	Weekly
MOTS-c	Per protocol	Weekly
SS-31	Per protocol	Daily or every other day

Outcome: Improved cellular repair, enhanced biological age markers, sleep quality, and mitochondrial function.

Archetype D — Sleep, Stress & CNS Recovery Protocol

Peptide / Product	Dose	Timing
CJC-1295 (No DAC) / Ipamorelin Blend	100–200/200 mcg SC	30–60 min pre-bed
DSIP	100–200 mcg SC	Pre-bed
KPV	Per protocol	If inflammation-driven insomnia

Outcome: Deepened sleep architecture, reduced cortisol burden, enhanced overnight recovery and CNS repair.

9. Expected Clinical Timeline

Days 3–7

Improved sleep quality, deeper sleep, enhanced morning recovery and energy

Weeks 1–2

Increased daily energy, improved mood, better exercise tolerance and resilience

Weeks 2–4

Fat loss begins, lean mass preservation evident, IGF-1 levels rising on labs

Weeks 4–8

Measurable body composition improvements, strength gains, improved skin quality

Months 2–6

Full GH-axis optimization, anti-aging effects, sustained metabolic and longevity benefits

10. Safety, Contraindications & Monitoring

Absolute Contraindications

Active cancer — particularly GH-sensitive tumors (pituitary, breast, prostate, colon)
Pregnancy
Lactation / breastfeeding

Relative Contraindications

Uncontrolled or unstable diabetes mellitus (GH can worsen insulin resistance)
Severe cardiovascular disease
Active proliferative retinopathy
Active systemic infection or sepsis
Known pituitary pathology — requires endocrinology co-management

Adverse Effects

The blend inherits the favorable tolerability profiles of both component peptides — fewer adverse effects than GHRP-2, GHRP-6, or exogenous GH therapy. The blend does NOT cause cortisol, prolactin, or ACTH elevation.

Effect	Details & Management
Water retention (mild)	Typically transient; resolves in 1–2 weeks. Reduce dose if bothersome.
Flushing / warmth	Mild, short-lived; more common at higher doses. Self-resolves.
Headache	Rare; associated with rapid GH rise. Reduce dose or titrate more slowly.
Tingling / paresthesias	Rare peripheral GH effect. Usually benign and transient.
Transient nausea	More common at higher doses. Ensure empty stomach pre-injection.
Injection site irritation	Rotate sites. Use proper sterile technique.
Increased appetite (mild)	Ghrelin-mimetic effect; usually mild and manageable.

Monitoring Parameters

Parameter	Recommended Schedule
IGF-1 (serum)	Baseline; recheck at 8–12 weeks on protocol
Fasting glucose & insulin	Baseline; 8–12 weeks (GH can affect insulin sensitivity)
Lipid panel	Baseline; annual or at 6-month intervals
Thyroid panel (TSH, Free T3/T4)	Baseline; optional follow-up if symptoms suggest change
Body composition	DEXA or bioimpedance at baseline and 12 weeks
Sleep quality (subjective)	Patient-reported at 2, 4, and 8 weeks

Legal Disclaimer

This document is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.

CJC-1295 (No DAC), Ipamorelin, and other peptides referenced herein are not FDA-approved drugs. Their clinical use may constitute off-label or investigational use. Any such use must comply with all applicable federal and state laws, medical board regulations, and scope-of-practice requirements governing your jurisdiction.

Peptide Protocol Portal®, its affiliates, authors, and contributors make no representations or warranties regarding accuracy, completeness, safety, or regulatory compliance. Clinical decisions remain the sole responsibility of the licensed practitioner.

References — CJC-1295 (No DAC) / Ipamorelin Blend

CJC-1295 (No DAC) / GHRH Analogs

1. Teichman SL, et al. Prolonged stimulation of GH and IGF-1 by CJC-1295. J Clin Endocrinol Metab, 91(3), 799–805 (2006).

2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone. Endocr Rev, 23(6), 523–542 (2002).

3. Bowers CY, et al. Synergistic GH release with GHRH + GHRP combinations. Endocrinology, 99(4), 1200–1205 (1986).

4. Ghigo E, et al. GH secretagogues: Mechanisms and clinical significance. Endocrinol Metab Clin North Am, 37(1), 101–122 (2008).

Ipamorelin / Ghrelin Pathway

5. Raun K, et al. Ipamorelin, the first selective GHS receptor agonist. Eur J Pharmacol, 381(1), 45–52 (1999).

6. Jacks T, et al. Ipamorelin vs. GHRP-6: Comparative GH, ACTH, and cortisol responses. J Clin Endocrinol Metab, 84(1), 25–30 (1999).

7. Kojima M, et al. Ghrelin is the endogenous ligand for the GH secretagogue receptor. Nature, 402(6762), 656–660 (1999).

GH Axis, Body Composition & Anti-Aging

8. Nass R, et al. GH secretion in aging adults enhanced by selective GH secretagogues. J Clin Endocrinol Metab, 93(4), 1276–1281 (2008).

9. Svensson J, et al. GH secretagogue-induced increase in sleep-related GH pulses. J Clin Endocrinol Metab, 89(1), 113–117 (2004).

10. Veldhuis JD, et al. Mechanistic basis of GH pulsatility and secretagogue responsiveness. Am J Physiol Endocrinol Metab, 280(3), E489–E498 (2001).